Table 1 Study characteristics
First author (Ref No.) | Year of publication | Journal | Location of trial | Study design | Duration of follow-up | Sample size | Treatment | Control |
|---|---|---|---|---|---|---|---|---|
Katholi [51] | 1998 | American Journal of Kidney Diseases | Springfield, Illinois | Parallel Group RCT with 2x2 factorial design | 2Â days | 39 | Allopurinol | Placebo |
Perez-Ruiz [56] | 1999 | Journal of Clinical Rheumatology | Pais Vasco, Spain | Parallel Group RCT | 9-12 months | 36 | Benzbromarone | Allopurinol |
Kamper [50] | 2001 | Clinical Transplantation | Herlev, Denmark | Cross-over RCT | 2Â weeks | 26 | Losartan | No treatment |
Schmidt [53] | 2001 | Nephrology Dialysis Transplantation | Vienna, Austria | Cross-over RCT | 3Â weeks | 13 | Losartan | Enalapril |
Doehner [35] | 2002 | Circulation | London, UK | Cross-over RCT | 2Â weeks | 14 | Allopurinol | Placebo |
Chanard [54] | 2003 | Nephrology Dialysis Transplantation | Three centres in France | Parallel Group RCT | 2Â months | 48 | Amlodipine | Tertatolol |
Siu [48] | 2006 | American Journal of Kidney Diseases | Hong Kong, China | Parallel Group RCT | 12Â months | 54 | Allopurinol | No treatment |
Liu [36] | 2007 | China Pharmacy | Guangzhou and Luzhou, China | Parallel Group RCT | 12Â months | 47 | Allopurinol | No treatment |
Sarris [34] | 2007 | Nephrology Dialysis Transplantation | Athens, Greece | Parallel Group RCT | 12Â months | 36 | Allopurinol | No treatment |
Lei [40] | 2009 | Shaanxi Medical Journal | Xi’an, China | Parallel Group RCT | 12 months | 57 | Allopurinol | No treatment |
Malaguarnera [55] | 2009 | Expert Opinion Pharmacotherapy | Catania, Italy | Parallel Group RCT | 2Â months | 38 | Rasburicase | Placebo |
Nouri-Majalan [52] | 2009 | Vascular Health and Risk Management | Yazd, Iran | Parallel Group RCT | 5Â days | 60 | Allopurinol and vitamin E | No treatment |
Deng [37] | 2010 | Journal of Practical Medicine | Beijing, China | Parallel Group RCT | 12Â months | 68 | Allopurinol | No treatment |
Goicoechea [44] | 2010 | Clinical Journal of American Soc of Neph | Madrid, Spain | Parallel Group RCT | 24Â months | 113 | Allopurinol | No treatment |
Momeni [46] | 2010 | Iranian Journal of Kidney Diseases | Isfahan, Iran | Parallel Group RCT | 4Â months | 44 | Allopurinol | Placebo |
Shen [38] | 2010 | China Foreign Medical Treatment | Chengdu, China | Parallel Group RCT | 12Â months | 52 | Allopurinol | No treatment |
Kao [45] | 2011 | Journal of American Soc of Neph | Dundee, UK | Parallel Group RCT | 9Â months | 67 | Allopurinol | Placebo |
Tan [39] | 2011 | Modern Hospital | Guangzhou, China | Parallel Group RCT | 24Â months | 140 | Allopurinol | No treatment |
Shi [47] | 2012 | Kidney and Blood Pressure Research | Guangzhou, China | Parallel Group RCT | 6Â months | 40 | Allopurinol | No treatment |